These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6128524)

  • 1. Factor VIII cryoprecipitate and hepatitis risk.
    Gabra GS; Crawford RJ; Mitchell R
    Lancet; 1982 Nov; 2(8309):1220. PubMed ID: 6128524
    [No Abstract]   [Full Text] [Related]  

  • 2. Cryoprecipitate as a reliable source of fibrinogen replacement.
    Ness PM; Perkins HA
    JAMA; 1979 Apr; 241(16):1690-1. PubMed ID: 430729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryoprecipitate and fibrinogen.
    Goodnight SH
    JAMA; 1979 Apr; 241(16):1716-7. PubMed ID: 430737
    [No Abstract]   [Full Text] [Related]  

  • 4. Incidence of infectious and noninfectious side effects in hemophilia patients in the new German Federal States during treatment with cryoprecipitate.
    Lenk H; Schneider M
    Semin Thromb Hemost; 2002 Apr; 28 Suppl 1():51-6. PubMed ID: 12016579
    [No Abstract]   [Full Text] [Related]  

  • 5. Preparation of pooled cryoprecipitate for treatment of hemophilia A in a home care program.
    Smith KJ; Hodges PA
    Transfusion; 1984; 24(6):520-3. PubMed ID: 6438840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of pasteurised factor VIII (haemate HS).
    Delvos V; Weidmann E; Hilfenhaus J; Mauler R
    Lancet; 1988 Nov; 2(8620):1141-2. PubMed ID: 2903355
    [No Abstract]   [Full Text] [Related]  

  • 7. [Plasma concentrates of factor VIII. Where are we?].
    Vicente V
    Sangre (Barc); 1989 Feb; 34(1):1-3. PubMed ID: 2496481
    [No Abstract]   [Full Text] [Related]  

  • 8. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
    McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
    Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of infection with hepatitis B virus in 56 patients with haemophilia A 1971-1979.
    Stirling ML; Murray JA; Mackay P; Black SH; Peutherer JF; Ludlam CA
    J Clin Pathol; 1983 May; 36(5):577-80. PubMed ID: 6404950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute fulminant non-A, non-B hepatitis leading to chronic active hepatitis after treatment with cryoprecipitate.
    Lee CA; Kernoff PB; Karayiannis P; Thomas HC
    Gut; 1985 Jun; 26(6):639-41. PubMed ID: 3924749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clearance of cryoprecipitated factor VIII in canine hemophilia A.
    Aufderheide WM; Skinner SF; Kaneko JJ
    Am J Vet Res; 1975 Apr; 36(4 Pt.1):367-70. PubMed ID: 1124873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of high-potency cryoprecipitate from exercised blood donors and the treatment of hemophilia A with this material.
    Strand CL; Beene JR; Geiger T; Eckel MO; Kunkel K; Bull G
    Am J Clin Pathol; 1974 Oct; 62(4):496-501. PubMed ID: 4415312
    [No Abstract]   [Full Text] [Related]  

  • 13. Utilization of the residual plasma following preparation of factor VIII cryoprecipitate.
    Oberman HA; Penner JA
    JAMA; 1968 Sep; 205(12):819-21. PubMed ID: 5695503
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma fibrinogen levels following cryoprecipitate infusion.
    Soloway HB; Bereznak CE
    Transfusion; 1970; 10(6):326-8. PubMed ID: 5490100
    [No Abstract]   [Full Text] [Related]  

  • 15. Freeze dried cryoprecipitate: a clinical evaluation.
    Hambley H; Davidson JF; Walker ID; Small M; Prentice CR
    J Clin Pathol; 1983 May; 36(5):574-6. PubMed ID: 6404949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advances in hemophilia treatment: a hepatitis-safe factor VIII concentrate].
    Heimburger N
    Blut; 1982 Apr; 44(4):249-51. PubMed ID: 6805537
    [No Abstract]   [Full Text] [Related]  

  • 17. Cryoprecipitate and the plastic blood-bag system: provision of adequate replacement therapy for routine treatment of haemophilia.
    Bennett E; Dormandy KM; Churchill WG; Coward AR; Smith M; Cleghorn TE
    Br Med J; 1967 Apr; 2(5544):88-91. PubMed ID: 6020855
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose requirement for replacement therapy in hemophilia A.
    Allain JP
    Thromb Haemost; 1979 Oct; 42(3):825-31. PubMed ID: 505399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent findings on hemophilia].
    Abe T; Kinoshita T
    Nihon Rinsho; 1981; 39(12):3647-56. PubMed ID: 6803031
    [No Abstract]   [Full Text] [Related]  

  • 20. A high-potency, single-donor cryoprecipitate of known factor VIII content dispensed in vials.
    McLeod BC; Sassetti RJ; Cole ER; Scott JP
    Ann Intern Med; 1987 Jan; 106(1):35-40. PubMed ID: 3098152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.